Navigation Links
Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
Date:2/3/2009

y. The primary efficacy endpoint of the study was the increase in mean daily "ON" time ("ON" time without dyskinesia plus "ON" time with minor dyskinesia) during an 18-hour period as assessed by patients' recordings on diary cards.

Out of the 669 randomized patients, 89% of patients treated with safinamide completed the study (91% in the 50 mg dose group and 87% in the 100 mg dose group) compared to 89% in the placebo group. Over 90% of patients who completed the initial 24 weeks of treatment elected to enter a 78-week, placebo-controlled double-blind extension study, which is ongoing, to specifically assess the effect on dyskinesias as primary endpoint.

Secondary efficacy endpoints of this study were also met, including decrease in daily "OFF" time, decrease in mean "OFF" time following first morning dose of levodopa, mean change from baseline in the Unified Parkinson's Disease Rating Scale (UPDRS)(2) Section III (motor) score during "ON" time and mean change in Clinical Global Impression of severity of disease and change from baseline (CGI)(3). The incidence of dropouts, serious adverse events or clinically notable events among the three groups of the study were comparable.

Full study results after completion of ongoing analyses will be submitted for presentation at upcoming scientific meetings.

Merck Serono has exclusive worldwide rights to develop, manufacture and commercialize safinamide in Parkinson's disease, Alzheimer's disease and other therapeutic applications, as per the agreement signed with Newron in 2006.

About safinamide

Safinamide, an alpha-aminoamide derivative that is orally formulated, is currently being developed by Merck Serono and Newron as an add-on treatment for patients with Parkinson's disease. Safinamide is believed to have a novel dual mechanism of action based on the enhancement of the dopaminergic function (through reversible inhib
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
2. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
3. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
4. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
5. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
9. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
10. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
11. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Calif. , Sept. 17, 2014  Neuraltus Pharmaceuticals, ... Company,s Phase 2 clinical program of NP001 for the ... Gehrig,s disease) are being highlighted today in an ... ALS Research Group , being held in ... a  post hoc  analysis, administration of a high dose ...
(Date:9/17/2014)... 2014  Fortune Oil and Gas, Inc. (OTCPink:FOGC), today ... Manzo Pharmaceuticals, Inc. with the symbol (OTCPink : FOGCD). ... 17, 2014. Also taking effect today is a ten ... a pivotal event in the company,s progress according to ... could not proceed with the plan and still have ...
(Date:9/17/2014)... Pa. , Sept. 17, 2014  Auxilium Pharmaceuticals, ... company, today confirmed that Auxilium has received an unsolicited, ... ENDP ) to acquire all of the outstanding shares ... per share in cash and Endo stock, subject to ... the unsolicited, non-binding proposal that Auxilium received from Endo ...
Breaking Medicine Technology:Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 2Neuraltus Pharmaceuticals' ALS Treatment Candidate, NP001, Highlighted at ALS Research Group Summit 3Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3Auxilium Responds To Unsolicited Proposal From Endo International 2Auxilium Responds To Unsolicited Proposal From Endo International 3Auxilium Responds To Unsolicited Proposal From Endo International 4Auxilium Responds To Unsolicited Proposal From Endo International 5Auxilium Responds To Unsolicited Proposal From Endo International 6Auxilium Responds To Unsolicited Proposal From Endo International 7
... CHICAGO, June 9, 2011 Today a Cook County jury ... Chicago area man, Steven Johansen, who was administered Baxter blood ...  This was the first of hundreds of pending lawsuits on ... are pending in the Circuit Court of Cook County in ...
... Inc. today announced an agreement with the U.S. Department of ... the marketing and promotion of Keppra®, an anti-epileptic prescription medicine. ... this investigation occurred more than six years ago, and as ... United States since learning of the investigation in 2008. ...
Cached Medicine Technology:Nolan Law Group: Jury Finds Against Baxter Healthcare In Nation's First Contaminated Chinese Heparin Case 2UCB, Inc. Resolves Investigation of Past Keppra® Marketing and Promotional Activities 2
(Date:9/17/2014)... September 17, 2014 In ongoing ... Inc.’s Drug Benefit News (DBN) continues to find ... in its Aug. 8 issue , CVS Caremark ... lists for 2015 each cut more drugs than ... savings these exclusions are likely to achieve. Despite ...
(Date:9/17/2014)... Washington, DC (PRWEB) September 17, 2014 ... family history. Along with regular screening and examination, a ... In this episode of Epicure with the Chef ... GWMFA Urologist Dr. Paul Rusilko to prepare a delicious ... in our western diets that influence risk of prostate ...
(Date:9/17/2014)... 2014 “North America Gynecological Devices ... on the North America Gynecological Devices market. The ... volume (in units) and average prices (in US ... Female Sterilization Devices (Transcervical Sterilization Devices (Micro-inserts) ... , Endometrial Ablation Devices (Thermal Balloon, ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Stand Up ... and music, returns to the Theater at Madison Square ... the Bob Woodruff Foundation (BWF) and New York Comedy ... returning service members, veterans and their families. , ... John Mulaney, John Oliver, Bruce Springsteen, Brian Williams and ...
(Date:9/17/2014)... Alpharetta, GA (PRWEB) September 17, 2014 ... Background Screeners (NAPBS®) Background Screening Credentialing Council ... demonstrated compliance with the Background Screening Agency ... formally recognized as BSCC-Accredited. , S2Verify, ... , Each year, U.S. employers, organizations and ...
Breaking Medicine News(10 mins):Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 2Health News:AIS Newsletter Continues to Find Industry Criticism of PBM Formulary Exclusion Lists 3Health News:Boost Prostate Health with Epicure with the Chef MDs 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 2Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 3Health News:Gynecological Devices Market in North America (US, Canada & Mexico) to 2020 New Report Available at MarketOptimizer.org 4Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 2Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 3Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 4Health News:Louis C.K., John Mulaney, John Oliver, Bruce Springsteen, Brian Williams & More to Perform at 8th Annual Stand Up for Heroes at Theater at Madison Square Garden, Nov. 5 5Health News:S2Verify Achieves Background Screening Credentialing Council Accreditation 2Health News:S2Verify Achieves Background Screening Credentialing Council Accreditation 3
... , , COLCHESTER, ... College of Pharmacy and Health Sciences opened its Vermont Satellite Campus ... in scenic Colchester, Vermont, is home to the only pharmacy program ... campus offers a four year program culminating in a Doctor of ...
... ... Eye Institute of Utah – a prominent Salt Lake City, Utah ... a national award recognizing the quality of its work. Known as one of ... Springs, Wyoming location has been named by the U.S. Commerce Association as one ...
... U.S. Commerce ... living with Diabetes. , ... Raton, FL (PRWEB) August 31, 2009 -- Leading provider of diabetes medical supplies, American Diabetes ... Medical Supplies category by the U.S. Commerce Association (USCA). The company is aiding those ...
... ... solution to address current challenges in public health reporting and to improve the early detection, ... , ... 2009 -- Orion Health, Inc. and Cisco today announced the Rhapsody® ...
... , , MAASTRICHT, ... VAR ) is introducing the world,s first low-energy radiotherapy ... clinics. Varian,s UNIQUE(TM) radiotherapy system is expected to make advanced ... around the world. , , "This package ...
... , , NUTLEY, N.J., ... that the U.S. Food and Drug Administration (FDA) has approved Valcyte(R) ... kidney and heart transplant patients (4 months to 16 years of ... also approved a new pediatric oral solution formulation for Valcyte, which ...
Cached Medicine News:Health News:Albany College of Pharmacy and Health Sciences Opens Vermont Satellite Campus 2Health News:The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association 2Health News:The Eye Institute Receives 2009 Best of Rock Springs Award from U.S. Commerce Association 3Health News:Provider of Diabetes Medical Supplies Receives 2009 Best of Boca Raton Award 2Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 2Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 3Health News:Orion Health and Cisco Announce New Medical Data Exchange Solution to Integrate, Share and Report Public Health Data 4Health News:Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics 2Health News:Varian Medical Systems Adds RapidArc(R) and Image Guidance to New Low Energy Treatment Platform for Radiation Therapy in International Cancer Clinics 3Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 2Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 3Health News:FDA Approves Valcyte(R) (valganciclovir hydrochloride) to Prevent Cytomegalovirus (CMV) Disease in Pediatric Patients Who Receive Heart or Kidney Transplants 4
... protection, our conventional aprons are ... sturdy 2 webbed straps that ... hook fasteners. The straps can ... the apron. Our conventional apron ...
Unshielded...
... Triage BNP Test is the first ... measuring B-type natriuretic peptide (BNP) ,Cardiac ... in response to ventricular volume expansion ... of ventricular systolic and diastolic dysfunction. ...
... MOST Options System is designed to ... of the knee or hip to ... provides the potential for restoration of ... the requirements of a rotating hinge ...
Medicine Products: